“The Japan oncology drugs market accounted for $9,405 million in 2018 and is expected to reach $14,109 million by 2026, registering a CAGR of 5.2% from 2019 to 2026.”
Cancer is a serious medical condition marked by the presence of tumor cells present in the body. The formation of tumor cells takes place when the normal cells grow at an abnormal rate. Moreover, these tumor cells also have the ability to spread to other parts of the body through the blood and lymphatic system. In addition, cancer has different stages which are based on the growth pattern of the tumor. Therefore, the treatment of cancer differs depending on the stage of cancer. Chemotherapy drugs are mostly employed in the treatment of early-stage cancers and similarly targeted therapy and immunotherapy drugs are generally preferred in the treatment of late-stage cancers.
The surge in research related to new drug discovery for cancer treatment, the rise in the incidence of cancer in Japan, and an increase in healthcare expenditure boost the growth of the Japan oncology drugs market. Moreover, the rise in awareness related to early diagnosis of cancer leading to a rise in demand for oncology drugs for treatment is another factor that fuels the growth of the market in Japan. Furthermore, the surge in the geriatric population also contributes to the growth of the market as the elderly are more prone to certain cancer such as prostate cancer. In addition, the rise in the number of pipeline products is expected to provide lucrative opportunities during the forecast period. Conversely, the stringent approval process of oncology drugs in Japan hinders the growth of the market.
The Japan oncology drugs market size is studied based on segments, drug class type, and indication. Based on drug class type, the market is divided into chemotherapy, targeted therapy, immunotherapy, hormonal therapy. By indication, it is categorized into blood cancer, breast cancer, gastrointestinal cancer, prostate cancer, lung cancer, skin cancer, ovarian cancer, cervical cancer, kidney cancer, and others.
KEY BENEFITS FOR STAKEHOLDERS
• The study provides an in-depth analysis of the market along with the current trends and future estimations to elucidate the imminent investment pockets.
• It offers a quantitative analysis from 2018 to 2026, which is expected to enable the stakeholders to capitalize on the prevailing market opportunities.
• The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the Japan market
• A qualitative analysis based on innovative products facilitates strategic business planning.
Key Market Segments
By Drug Class Type
• Targeted Therapy
• Immunotherapy (Biologic Therapy)
• Hormonal Therapy
• Blood Cancer
• Breast Cancer
• Gastrointestinal Cancer
• Prostate Cancer
• Lung Cancer
• Skin Cancer
• Ovarian Cancer
• Cervical Cancer
• Other Cancers
List of key players profiled in the report:
• Otsuka Holdings Co Ltd
• Johnson and Johnson
• Daiichi Sankyo Co Ltd
• AstraZeneca plc
• AbbVie Inc.
• Celgene Corporation
• Bristol-Myers Squibb Company
• F. Hoffmann-La Roche AG
• Astellas Pharma Inc.
• Takeda Pharmaceutical Company Ltd
LIST of OTHER PLAYERS IN THE VALUE CHAIN (These players are not profiled in the report. The same will be included on request)
• Amgen Inc.
• Bayer AG
To request a sample copy or view summary of this report, click the link below:
About Digits N Markets:
Digits N Markets has a vast repository of latest market research reports on trending topics, niche company profiles, market size and other relevant data released by renowned publishers. We have access to the database related to niche markets and trending topics in various industries. We also update the data regularly to provide recent statistics to the client. Recent data and reports will be featured on our websites and clients will be able to access the same. Our clients will be able to benefit from qualitative & quantitative insights in the report which will support them in taking concrete business decisions.